EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

James G Krueger, John Frew, Gregor B E Jemec, Alexa B Kimball, Brian Kirby iD, Falk G Bechara, Kristina Navrazhina, Errol Prens, Kristian Reich, Eva Cullen, Kerstin Wolk iD

British Journal of Dermatology · 23.01.2024 · 190 (2) · 149-162

DOI: 10.1093/bjd/ljad345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 16.09.2023. Verfasst von James G Krueger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MoonLake Immunotherapeutics AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1–2%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-α and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-α antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic ‘window of opportunity’; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaHumansTumor Necrosis Factor InhibitorsAdalimumabTumor Necrosis Factor-alphaAbscess

Substanzen

Tumor Necrosis Factor InhibitorsAdalimumabTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.
  • Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia.
  • Department of Dermatology, Liverpool Hospital, Sydney, Australia.
  • University of New South Wales, Sydney, Australia.
  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Brian Kirby, Kerstin Wolk

Förderung

  • MoonLake Immunotherapeutics AG

Zitieren

APA

Krueger, J. G., Frew, J., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E., Reich, K., Cullen, E., & Wolk, K. (2024). Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. British Journal of Dermatology, 190(2), 149-162. https://doi.org/10.1093/bjd/ljad345

Vancouver

Krueger JG, Frew J, Jemec GBE, Kimball AB, Kirby B, Bechara FG, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. British Journal of Dermatology. 2024;190(2):149-162. doi:10.1093/bjd/ljad345

BibTeX
@article{Krueger2024,
  author = {Krueger, James G and Frew, John and Jemec, Gregor B E and Kimball, Alexa B and Kirby, Brian and Bechara, Falk G and Navrazhina, Kristina and Prens, Errol and Reich, Kristian and Cullen, Eva and Wolk, Kerstin},
  title = {Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape},
  journal = {British Journal of Dermatology},
  year = {2024},
  volume = {190},
  number = {2},
  pages = {149--162},
  doi = {10.1093/bjd/ljad345}
}
Kostenlos starten →